The U.S. Food and Drug Administration has approved ethiodized oil injection (Lipiodol) for selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma. The agent received orphan drug designation for management of patients with known hepatocellular carcinoma in October 2013.
Ethiodized oil, an oil-based radiopaque contrast agent, is also indicated for hysterosalpingography in adults and lymphography in adult and pediatric patients. The agent is contraindicated in patients with hypersensitivity to ethiodized oil, hyperthyroidism, traumatic injuries, recent hemorrhage, or bleeding. ■
